Table 3.

Discontinuations (several reasons could be given in parallel

	Etanercept	Tocilizumab	Interleukin-1 inhibitor
Discontinuations	77 (53.8%)	28 (39.4%)	28 (46.7%)
Inefficacy	62 (43.4%)	6 (8.5%)	13 (21.7%)
Intolerance	5 (3.5%)	14 (19.7%)	1 (1.7)
Remission	0	18 (25.4%)	11 (18.3)
Othersa	15 (10.5%)	3 (4.2%)	3 (5.0%)

^aOther reasons: in the etanercept cohort, patient’s/parent’s wish (n = 6); no further visits by the patient (n = 2), treatment with approved biologic available (n = 2), no restart after an adverse event although it disappeared (n = 2), reason not reported (n = 3); in patients on anakinra, a patient was admitted to a clinical trial (n = 1), reason not reported (n = 2); in patients on tocilizumab, reason not reported (n = 3)